Skip to main content
SpringerLink
Log in

Genetic Syndromes and RT for Breast Cancer

  • Chapter
  • First Online:
Breast Cancer Radiation Therapy

  • 648 Accesses

Abstract

This chapter discusses hereditary predisposition for developing breast cancer and focuses also on hereditary predisposition in relation to radiation therapy–related complications. We discuss current evidence and international guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820–3.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1(2):157–62.

    Article  CAS  PubMed  Google Scholar 

  3. Apostolou P, Fostira F. Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int. 2013;2013:747318.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–30.

    Article  CAS  PubMed  Google Scholar 

  5. Peleg Hasson S, Menes T, Sonnenblick A. Comparison of patient susceptibility genes across breast cancer: implications for prognosis and therapeutic outcomes. Pharmgenomics Pers Med. 2020;13:227–38.

    PubMed  PubMed Central  Google Scholar 

  6. Michailidou K, Lindstrom S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Brentnall AR, van Veen EM, Harkness EF, Rafiq S, Byers H, Astley SM, et al. A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. Int J Cancer. 2020;146(8):2122–9.

    Article  CAS  PubMed  Google Scholar 

  8. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, Dowsett M, Forbes JF, Ford L, LaCroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381(9880):1827–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A, IBIS-II investigators. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet. 2020;395(10218):117–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, et al. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat. 2013;142(3):611–8.

    Article  CAS  PubMed  Google Scholar 

  11. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266(5182):66–71.

    Article  CAS  PubMed  Google Scholar 

  12. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.

    Article  CAS  PubMed  Google Scholar 

  13. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812–22.

    Article  CAS  PubMed  Google Scholar 

  14. Wong-Brown MW, Meldrum CJ, Carpenter JE, Clarke CL, Narod SA, Jakubowska A, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(1):71–80.

    Article  CAS  PubMed  Google Scholar 

  15. van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34(2):71–88.

    Article  CAS  Google Scholar 

  16. Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, et al. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 2018;9:909.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Park H, Choi DH, Noh JM, Huh SJ, Park W, Nam SJ, et al. Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations. Int J Radiat Biol. 2014;90(1):90–4.

    Article  CAS  PubMed  Google Scholar 

  18. Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, et al. Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom. Clin Cancer Res. 2006;12(23):7025–32.

    Article  CAS  PubMed  Google Scholar 

  19. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000;18(19):3360–9.

    Article  CAS  PubMed  Google Scholar 

  20. Bernstein JL, Thomas DC, Shore RE, Robson M, Boice JD Jr, Stovall M, et al. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer. 2013;49(14):2979–85.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, et al. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. Breast Cancer Res Treat. 2015;154(1):171–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, et al. Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2011;104(9):1384–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pierce LJ, Phillips KA, Griffith KA, Buys S, Gaffney DK, Moran MS, et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010;121(2):389–98.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Evron E, Ben-David AM, Goldberg H, Fried G, Kaufman B, Catane R, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Ann Oncol. 2019;30(3):412–7.

    Article  CAS  PubMed  Google Scholar 

  25. Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, et al. Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020;38(18):2080–106.

    Article  CAS  PubMed  Google Scholar 

  26. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.

    Article  CAS  PubMed  Google Scholar 

  27. Spurdle AB, Couch FJ, Parsons MT, McGuffog L, Barrowdale D, Bolla MK, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16(6):3419.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22(6):719–29.

    Article  CAS  PubMed  Google Scholar 

  29. Zhang F, Fan Q, Ren K, Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res. 2009;7(7):1110–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384:440.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Breast Cancer Association Consortium. Breast cancer risk genes—association analysis in more than 113,000 women. N Engl J Med. 2021;384:428.

    Article  Google Scholar 

  32. Zhou J, Wang H, Fu F, Li Z, Feng Q, Wu W, et al. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing. Cancer. 2020;126(14):3202–8. https://doi.org/10.1002/cncr.32905. Epub 2020 Apr 27

    Article  CAS  PubMed  Google Scholar 

  33. Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen general population study. J Clin Oncol. 2016;34(11):1208–16.

    Article  PubMed  CAS  Google Scholar 

  34. Bergstrom C, Pence C, Berg J, Partain N, Sadeghi N, Mauer C, et al. Clinicopathological features and outcomes in individuals with breast cancer and ATM, CHEK2, or PALB2 mutations. Ann Surg Oncol. 2020;28:3383.

    Article  PubMed  Google Scholar 

  35. Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser. 1985;19:1–63.

    CAS  PubMed  Google Scholar 

  36. Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol. 2016;40(5):425–31.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kastan M. Ataxia-telangiectasia--broad implications for a rare disorder. N Engl J Med. 1995;333(10):662–3.

    Article  CAS  PubMed  Google Scholar 

  38. Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. J Natl Cancer Inst. 2010;102(7):475–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Varghese S, Schmidt-Ullrich RK, Dritschilo A, Jung M. Enhanced radiation late effects and cellular radiation sensitivity in an ATM heterozygous breast cancer patient. Radiat Oncol Investig. 1999;7(4):231–7.

    Article  CAS  PubMed  Google Scholar 

  40. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, et al. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007;9(2):R26.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA. 2001;286(18):2233–4.

    Article  CAS  PubMed  Google Scholar 

  42. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392(6674):402–5.

    Article  CAS  PubMed  Google Scholar 

  43. Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386–e97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.

    Article  CAS  PubMed  Google Scholar 

  45. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary diffuse gastric cancer syndrome: CDH1 mutations and beyond. JAMA Oncol. 2015;1(1):23–32.

    Article  PubMed  Google Scholar 

  46. Corso G, Intra M, Trentin C, Veronesi P, Galimberti V. CDH1 germline mutations and hereditary lobular breast cancer. Familial Cancer. 2016;15(2):215–9.

    Article  CAS  PubMed  Google Scholar 

  47. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233–8.

    Article  CAS  PubMed  Google Scholar 

  48. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet. 2010;47(6):421–8.

    Article  CAS  PubMed  Google Scholar 

  49. Wilson JR, Bateman AC, Hanson H, An Q, Evans G, Rahman N, et al. A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet. 2010;47(11):771–4.

    Article  CAS  PubMed  Google Scholar 

  50. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345–52.

    Article  CAS  PubMed  Google Scholar 

  51. Heymann S, Delaloge S, Rahal A, Caron O, Frebourg T, Barreau L, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Ferrarini A, Auteri-Kaczmarek A, Pica A, Boesch N, Heinimann K, Schafer SC, et al. Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53. Familial Cancer. 2011;10(2):187–92.

    Article  PubMed  Google Scholar 

  53. Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, et al. Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. J Natl Compr Cancer Netw. 2012;10(8):939–42.

    Article  Google Scholar 

  54. Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer. 2001;96(4):238–42.

    Article  CAS  PubMed  Google Scholar 

  55. Salmon A, Amikam D, Sodha N, Davidson S, Basel-Vanagaite L, Eeles RA, et al. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. Clin Oncol (R Coll Radiol). 2007;19(7):490–3.

    Article  CAS  Google Scholar 

  56. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.

    Article  CAS  PubMed  Google Scholar 

  57. Tchekmedyian A, Amos CI, Bale SJ, Zhu D, Arold S, Berrueta J, et al. Findings from the Peutz-Jeghers syndrome registry of Uruguay. PLoS One. 2013;8(11):e79639.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Georgescu MM. PTEN tumor suppressor network in PI3K-Akt pathway control. Genes Cancer. 2010;1(12):1170–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet. 1999;7(3):267–73.

    Article  CAS  PubMed  Google Scholar 

  60. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255–63.

    Article  CAS  PubMed  Google Scholar 

  61. Tatebe K, Chmura SJ, Connell PP. Elevated radiation therapy toxicity in the setting of germline PTEN mutation. Pract Radiat Oncol. 2019;9(6):492–5.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24(16):2437–43.

    Article  PubMed  Google Scholar 

  63. Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst Rev. 2018;4:CD002748.

    PubMed  Google Scholar 

  64. Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, Ausems MG, Collee JM, Jansen L, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136(3):668–77.

    CAS  PubMed  Google Scholar 

  65. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

  67. Lee KT, Mun GH. Prosthetic breast reconstruction in previously irradiated breasts: a meta-analysis. J Surg Oncol. 2015;112(5):468–75.

    Article  PubMed  Google Scholar 

  68. van Os NJ, Roeleveld N, Weemaes CM, Jongmans MC, Janssens GO, Taylor AM, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90(2):105–17.

    Article  PubMed  CAS  Google Scholar 

  69. Brooks JD, Teraoka SN, Reiner AS, Satagopan JM, Bernstein L, Thomas DC, et al. Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat. 2012;33(1):158–64.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Unit, Oncology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel

    Rinat Bernstein-Molho & Bella Kaufman

  2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Rinat Bernstein-Molho & Bella Kaufman

  3. University of Sheffield, Sheffield, UK

    Lynda Wyld

  4. Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust, Doncaster, UK

    Lynda Wyld

Authors
  1. Rinat Bernstein-Molho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bella Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lynda Wyld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rinat Bernstein-Molho .

Editor information

Editors and Affiliations

  1. Radiation Oncology Unit, Sheba Medical Center, Ramat Gan, Israel

    Orit Kaidar-Person

  2. Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

    Icro Meattini

  3. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

    Philip Poortmans

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bernstein-Molho, R., Kaufman, B., Wyld, L. (2022). Genetic Syndromes and RT for Breast Cancer. In: Kaidar-Person, O., Meattini, I., Poortmans, P. (eds) Breast Cancer Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-91170-6_48

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-91170-6_48

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-91169-0

  • Online ISBN: 978-3-030-91170-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation